Ninth Circuit judges won’t immediately decide if red states can join a lawsuit challenging the US’s regulation of mifepristone, a drug that induces abortions.
The US Food and Drug Administration’s heightened rules for the drug, known as the Risk Evaluation and Mitigation Strategy, will be considered by the US Supreme Court March 26. The top court will decide if a federal judge in Texas correctly voided the agency’s approval of the drug for use in terminating pregnancies up until about 10 weeks. If affirmed, the ruling likely will make mifepristone unavailable nationwide.
The top court will hear arguments on issues ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.